Financials
Financial year 2025
GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline from Wavre, company number BE0403066474, closed financial year 2025 with a result of € 7 million after tax. For that financial year GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline recorded revenue of € 241.2 million and equity of € 4.8 million. Compared with financial year 2024, the result moved from € 5.3 million to € 7 million. Profitable, and profit is growing. The buffer shrank hard: equity is 58 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.
€ 4.8 million
▼ 58% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 7 million
▲ 33% vs 2024
Profit after tax over the fiscal year.
€ 13.5 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
194.7
▲ 0.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 38 million
▼ 1% vs 2024
€ 195,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 7.1 million
▼ 40% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 14 days on average.
€ 21.1 million
▲ 29% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 156,101,547 | € 187,464,693 | € 213,378,071 | € 241,221,934 | ▲ 13% |
| Profit after taxes | € 2,425,065 | € 4,134,594 | € 5,286,523 | € 7,028,949 | ▲ 33% |
| Equity | € 21,227,268 | € 25,361,862 | € 11,248,386 | € 4,778,595 | ▼ 58% |
| Total debts | € 25,952,331 | € 33,870,964 | € 48,401,403 | € 52,839,399 | ▲ 9% |
| Retained profit | € 17,094,715 | € 21,229,309 | € 7,115,833 | € 646,042 | ▼ 91% |
| Dividend | € 3,006,171 | € 0 | € 19,400,000 | € 13,498,740 | ▼ 30% |
| Balance sheet total | € 48,257,600 | € 60,066,480 | € 60,545,751 | € 58,188,896 | ▼ 4% |
| Employees (FTE) | 189.2 | 192.9 | 194.3 | 194.7 | ▲ 0.4 |
Key figures of GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline?
What happened at GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 7 million (▲ 33% vs 2024). Source: NBB ↗
- Vincent Willemant stepped down as director. NBB
- Frédéric Martin stepped down as director. NBB
- Frédéric Martin became a director. NBB
- Vincent Willemant became a director. NBB
- New establishment in Wavre. KBO
- Start of the company according to the CBE. KBO
In short
From € 2.4 million profit in 2022 to € 7 million profit in 2025.
Paid € 8.7 million in corporate taxes since 2022.
Best year ever: 2025, with € 7 million profit.
Paid out € 35.9 million in dividends to the owners in total.
A new publication or filing at GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline? We notify you, reason included.
Follow GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKlineDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Setfirst Ltd (100%) and Edinburgh Pharmaceutical Industries Ltd (0%).
Directors
According to the 2025 annual accounts
Vincent Willemant
Director
since 2025 · until 2026
Frédéric Martin
Managing director
Also active at: ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE
since 2025 · until 2026
Shareholders
Setfirst Ltd
100%
Edinburgh Pharmaceutical Industries Ltd
0%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Avenue Fleming 20
1300 Wavre
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0403.066.474
- VAT number
- BE 0403.066.474
- Registered office
- Avenue Fleming 20, 1300 Wavre
- Names & denominations
- GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline · GSK
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 1 January 1968
- Peppol
- Active · Active since 28 Oct 2025
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen